FDA Advisors Met To Consider AvertD Genetic Testing For Opioid Use Disorder

On October 20, 2022, members of the U.S. Food & Drug Administration's (FDA's) Clinical Chemistry and Clinical Toxicology Devices Advisory Committee met to discuss SOLVD's AvertD, a prescription genetic risk assessment tool for opioid use disorder (OUD). The committee's recommendation has not yet been released.

AvertD detects the presence or absence of 15 single nucleotide polymorphisms (SNPs) to help identify adults with an increased genetic risk of OUD. It is intended to be used in combination with clinical evaluations and consumer assessments when oral prescription opioids are being considered to treat acute pain. A version . . .